A phase 1c trial comparing the efficacy and safety of a new aqueous formulation of alphaxalone with propofol

John Monagle, W Lyndon Siu, Jodie Worrell, Colin Stanley Goodchild, Juliet M Serrao

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

Abstract

Phaxan (PHAX, Chemic Labs, Canton, MA) is an aqueous solution of 10 mg/mL alphaxalone and 13 7-sulfobutylether beta-cyclodextrin (betadex). In preclinical studies, PHAX is a fast onset-offset IV anesthetic like propofol, but causes less cardiovascular depression. This first-in-man study was designed to find the anesthetic dose of PHAX and to compare it with an equivalent dose of propofol for safety, efficacy, and quality of recovery from anesthesia and sedation. METHODS: The study adhered to compliance with Good Clinical Practices regulations (clinical trials registry number, ACTRN12611000343909). This randomized, double-blind study compared PHAX and propofol using a Bayesian algorithm to determine dose equivalence for effects on the bispectral index (BIS). Male volunteers, ASA physical status I, gave written informed consent (n = 12 per group; PHAX or propofol). Parameters assessed for 80 minutes after drug injection (single bolus dose) were pain on injection, involuntary movement, BIS, blood pressure, need for airway support, and, as measures of recovery from sedation, the Richmond Agitation and Sedation Scale and the Digit Symbol Substitution Test. Arterial blood was withdrawn for biochemistry, hematology, and complement levels. RESULTS: No subject complained of pain on injection with PHAX, whereas 8 of the 12 subjects given propofol did. Nine PHAX and 8 propofol subjects reached BIS values of
Original languageEnglish
Pages (from-to)914 - 924
Number of pages11
JournalAnesthesia and Analgesia
Volume121
Issue number4
DOIs
Publication statusPublished - 2015

Cite this